featured
Intrathecal Trastuzumab in HER2+ Breast Leptomeningeal Disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Breast Cancer Research and Treatment
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Intrathecal Trastuzumab in the Management of HER2+ Breast Leptomeningeal Disease: A Single Institution Experience
Breast Cancer Res Treat 2018 Feb 01;[EPub Ahead of Print], NB Figura, W Long, M Yu, TJ Robinson, S Mokhtari, AB Etame, ND Tran, R Diaz, H Soliman, HS Han, S Sahebjam, PA Forsyth, KA AhmedFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.